Microgynon 50 (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the active ingredient in Microgynon 50, is a combined oral contraceptive presented as a 0.03 mg/0.15 mg tablet for oral use. It prevents pregnancy in women of reproductive age and can help regulate menstrual cycles. GNH USA supplies Microgynon 50 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Microgynon 50 is a combined hormonal contraceptive that acts on the reproductive endocrine system. - Contraception: provides reliable prevention of pregnancy for women of child‑bearing potential. - Regulation of menstrual cycles: helps achieve more predictable and lighter bleeding patterns. - Acne treatment: reduces inflammatory acne lesions by modulating androgen activity.

Microgynon 50 may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort of the breasts. - Spotting or breakthrough bleeding: irregular light bleeding between periods. - Mood changes: irritability or mild depressive symptoms. - Weight gain: modest increase in body weight, usually fluid‑related.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in the legs. - Pulmonary embolism: clot migration to the lungs, a medical emergency. - Stroke or myocardial infarction: rare cerebrovascular or cardiac events. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver tumor: benign hepatic adenoma, especially with prolonged use. - Hypertension: new‑onset or worsening high blood pressure.

Before prescribing Microgynon 50, clinicians should evaluate individual risk factors and counsel patients on safe use. - Medical review: assess history of thromboembolic disorders, cardiovascular disease, or liver dysfunction. - Smoking: avoid use in women over 35 who smoke, due to increased clot risk. - Medication review: consider potential interactions with enzyme‑inducing drugs. - Pregnancy: discontinue immediately if pregnancy is confirmed; the product is not indicated for use during pregnancy. - Breastfeeding: discuss benefits and risks with a healthcare professional before use. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Microgynon 50 can interact with several drug classes, affecting contraceptive efficacy or hormone levels.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): markedly reduce hormonal effectiveness. - Rifampicin: lowers plasma concentrations of both estrogen and progestogen. - Protease inhibitor ritonavir: may increase hormone levels, raising risk of side effects.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., ketoconazole, itraconazole): can elevate hormone concentrations. - St. John’s wort: may modestly decrease contraceptive efficacy. - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly reduce protection, warranting backup contraception.